Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
LENNON - QUININE SULPHATE 300 MG TABLETS SCHEDULING STATUS: S2 Muscle relaxant S4 Anti-malarial PROPRIETARY NAME (and dosage form): LENNON - QUININE SULPHATE 300 MG TABLETS COMPOSITION: Each tablet contains 300 mg Quinine Sulphate. PHARMACOLOGICAL CLASSIFICATION: A 17.1 Peripherally acting muscle relaxants. PHARMACOLOGICAL ACTION: Quinine is a highly active blood schizonticide and suppresses the asexual cycle of development of malaria parasites in the erythrocytes. It is effective both as a suppressive drug and in the overt clinical attack of malaria. In addition quinine exerts relaxant effects on skeletal muscle. It increases the tension responses to a single maximal stimulus delivered to the muscle directly or through the nerve but it increases the refractory period of muscle so that the response to tetanic stimulation is reduced. Recumbency leg muscle cramps and myotonia congenita are thus effectively relieved by treatment with quinine. INDICATIONS: Quinine sulphate tablets are indicated mainly in the resistant strains of plasmodium falciparum malaria. It is also indicated as a muscle relaxant in myotonia congenita and myotonic contraction as well as nocturnal muscle cramps. A secondary indication is its use in the diagnostic test for myasthenia gravis. CONTRA-INDICATIONS: Quinine and its salts are contra-indicated in patients with a history of hypersensitivity to quinine and in patients with tinnitus or optic neuritis and especially when this takes the form of cutaneous, angioedematous, visual, or auditory symptoms. Quinine should be discontinued immediately if evidence of haemolysis appears. Pregnancy in a patient with malaria is not generally regarded as a contra-indication to the use of quinine, as malaria infection is potentially serious during pregnancy and poses a thr Read the complete document